Mechanism of third signals provided by IL-12 and OX-40R ligation in eliciting therapeutic immunity following dendritic-tumor fusion vaccination

Hideyuki Kuriyama, Satoshi Watanabe, Jorgen Kjaergaard, Hidemasa Tamai, Rongxiu Zheng, Andrew D. Weinberg, Hong Ming Hu, Peter A Cohen, Gregory E. Plautz, Suyu Shu

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Dendritic-tumor heterokaryons generated by electrofusion are highly immunogenic. In animal studies, a single vaccination was therapeutic for tumors established in the lung, skin, and brain. However, effective therapy required a third signal which could be provided by exogenous IL-12 or the agonistic anti-OX-40R monoclonal antibody (mAb). In this study, we investigated the mechanism and mode of actions of these two seemingly distinct adjuvants. In immunotherapy of the MCA205 sarcoma, administration of the neutralizing anti-IL-12 mAb nearly completely blocked the adjuvant effect of IL-12, but had minimal inhibitory effects on anti-OX-40R mAb. By contrast, in vivo administration of the antagonistic anti-OX-40L mAb inhibited the adjuvant effects of both IL-12 and anti-OX-40R mAb. Thus, a common pathway of endogenous OX-40 interaction is critical for the development of a therapeutic immune response. Analysis of the third signal mechanism revealed that in the absence of an adjuvant, vaccination with fusion hybrids led to IL-10 production without eliciting IFN-γ secreting cells. The addition of IL-12 to vaccination suppressed IL-10 production and initiated sensitization of specific IFN-γ secreting cells, resulting in a type 1-like antitumor immunity. These findings underscore the significance of the third signal in the design of dendritic cell-based cancer vaccines.

Original languageEnglish (US)
Pages (from-to)30-40
Number of pages11
JournalCellular Immunology
Volume243
Issue number1
DOIs
StatePublished - 2006
Externally publishedYes

Fingerprint

Interleukin-12
Ligation
Immunity
Vaccination
Monoclonal Antibodies
Neoplasms
Interleukin-10
Therapeutics
Cancer Vaccines
Sarcoma
Immunotherapy
Dendritic Cells
Lung
Skin
Brain

Keywords

  • Active immunotherapy
  • DC-tumor electrofusion hybrids
  • IL-12
  • OX-40R/OX-40L interaction

ASJC Scopus subject areas

  • Cell Biology
  • Immunology

Cite this

Mechanism of third signals provided by IL-12 and OX-40R ligation in eliciting therapeutic immunity following dendritic-tumor fusion vaccination. / Kuriyama, Hideyuki; Watanabe, Satoshi; Kjaergaard, Jorgen; Tamai, Hidemasa; Zheng, Rongxiu; Weinberg, Andrew D.; Hu, Hong Ming; Cohen, Peter A; Plautz, Gregory E.; Shu, Suyu.

In: Cellular Immunology, Vol. 243, No. 1, 2006, p. 30-40.

Research output: Contribution to journalArticle

Kuriyama, Hideyuki ; Watanabe, Satoshi ; Kjaergaard, Jorgen ; Tamai, Hidemasa ; Zheng, Rongxiu ; Weinberg, Andrew D. ; Hu, Hong Ming ; Cohen, Peter A ; Plautz, Gregory E. ; Shu, Suyu. / Mechanism of third signals provided by IL-12 and OX-40R ligation in eliciting therapeutic immunity following dendritic-tumor fusion vaccination. In: Cellular Immunology. 2006 ; Vol. 243, No. 1. pp. 30-40.
@article{24fb6cffdc0a4521a5d67141e6f29134,
title = "Mechanism of third signals provided by IL-12 and OX-40R ligation in eliciting therapeutic immunity following dendritic-tumor fusion vaccination",
abstract = "Dendritic-tumor heterokaryons generated by electrofusion are highly immunogenic. In animal studies, a single vaccination was therapeutic for tumors established in the lung, skin, and brain. However, effective therapy required a third signal which could be provided by exogenous IL-12 or the agonistic anti-OX-40R monoclonal antibody (mAb). In this study, we investigated the mechanism and mode of actions of these two seemingly distinct adjuvants. In immunotherapy of the MCA205 sarcoma, administration of the neutralizing anti-IL-12 mAb nearly completely blocked the adjuvant effect of IL-12, but had minimal inhibitory effects on anti-OX-40R mAb. By contrast, in vivo administration of the antagonistic anti-OX-40L mAb inhibited the adjuvant effects of both IL-12 and anti-OX-40R mAb. Thus, a common pathway of endogenous OX-40 interaction is critical for the development of a therapeutic immune response. Analysis of the third signal mechanism revealed that in the absence of an adjuvant, vaccination with fusion hybrids led to IL-10 production without eliciting IFN-γ secreting cells. The addition of IL-12 to vaccination suppressed IL-10 production and initiated sensitization of specific IFN-γ secreting cells, resulting in a type 1-like antitumor immunity. These findings underscore the significance of the third signal in the design of dendritic cell-based cancer vaccines.",
keywords = "Active immunotherapy, DC-tumor electrofusion hybrids, IL-12, OX-40R/OX-40L interaction",
author = "Hideyuki Kuriyama and Satoshi Watanabe and Jorgen Kjaergaard and Hidemasa Tamai and Rongxiu Zheng and Weinberg, {Andrew D.} and Hu, {Hong Ming} and Cohen, {Peter A} and Plautz, {Gregory E.} and Suyu Shu",
year = "2006",
doi = "10.1016/j.cellimm.2006.11.002",
language = "English (US)",
volume = "243",
pages = "30--40",
journal = "Cellular Immunology",
issn = "0008-8749",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Mechanism of third signals provided by IL-12 and OX-40R ligation in eliciting therapeutic immunity following dendritic-tumor fusion vaccination

AU - Kuriyama, Hideyuki

AU - Watanabe, Satoshi

AU - Kjaergaard, Jorgen

AU - Tamai, Hidemasa

AU - Zheng, Rongxiu

AU - Weinberg, Andrew D.

AU - Hu, Hong Ming

AU - Cohen, Peter A

AU - Plautz, Gregory E.

AU - Shu, Suyu

PY - 2006

Y1 - 2006

N2 - Dendritic-tumor heterokaryons generated by electrofusion are highly immunogenic. In animal studies, a single vaccination was therapeutic for tumors established in the lung, skin, and brain. However, effective therapy required a third signal which could be provided by exogenous IL-12 or the agonistic anti-OX-40R monoclonal antibody (mAb). In this study, we investigated the mechanism and mode of actions of these two seemingly distinct adjuvants. In immunotherapy of the MCA205 sarcoma, administration of the neutralizing anti-IL-12 mAb nearly completely blocked the adjuvant effect of IL-12, but had minimal inhibitory effects on anti-OX-40R mAb. By contrast, in vivo administration of the antagonistic anti-OX-40L mAb inhibited the adjuvant effects of both IL-12 and anti-OX-40R mAb. Thus, a common pathway of endogenous OX-40 interaction is critical for the development of a therapeutic immune response. Analysis of the third signal mechanism revealed that in the absence of an adjuvant, vaccination with fusion hybrids led to IL-10 production without eliciting IFN-γ secreting cells. The addition of IL-12 to vaccination suppressed IL-10 production and initiated sensitization of specific IFN-γ secreting cells, resulting in a type 1-like antitumor immunity. These findings underscore the significance of the third signal in the design of dendritic cell-based cancer vaccines.

AB - Dendritic-tumor heterokaryons generated by electrofusion are highly immunogenic. In animal studies, a single vaccination was therapeutic for tumors established in the lung, skin, and brain. However, effective therapy required a third signal which could be provided by exogenous IL-12 or the agonistic anti-OX-40R monoclonal antibody (mAb). In this study, we investigated the mechanism and mode of actions of these two seemingly distinct adjuvants. In immunotherapy of the MCA205 sarcoma, administration of the neutralizing anti-IL-12 mAb nearly completely blocked the adjuvant effect of IL-12, but had minimal inhibitory effects on anti-OX-40R mAb. By contrast, in vivo administration of the antagonistic anti-OX-40L mAb inhibited the adjuvant effects of both IL-12 and anti-OX-40R mAb. Thus, a common pathway of endogenous OX-40 interaction is critical for the development of a therapeutic immune response. Analysis of the third signal mechanism revealed that in the absence of an adjuvant, vaccination with fusion hybrids led to IL-10 production without eliciting IFN-γ secreting cells. The addition of IL-12 to vaccination suppressed IL-10 production and initiated sensitization of specific IFN-γ secreting cells, resulting in a type 1-like antitumor immunity. These findings underscore the significance of the third signal in the design of dendritic cell-based cancer vaccines.

KW - Active immunotherapy

KW - DC-tumor electrofusion hybrids

KW - IL-12

KW - OX-40R/OX-40L interaction

UR - http://www.scopus.com/inward/record.url?scp=33847068762&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847068762&partnerID=8YFLogxK

U2 - 10.1016/j.cellimm.2006.11.002

DO - 10.1016/j.cellimm.2006.11.002

M3 - Article

C2 - 17207783

AN - SCOPUS:33847068762

VL - 243

SP - 30

EP - 40

JO - Cellular Immunology

JF - Cellular Immunology

SN - 0008-8749

IS - 1

ER -